We are live on ! Find out more
JGUA

John G. Ullman & Associates Portfolio holdings

AUM $754M
1-Year Est. Return 60.05%
This Fund
S&P 500
This Quarter Est. Return
+3.93%
1 Year Est. Return
+60.05%
3 Year Est. Return
+108.28%
5 Year Est. Return
+118.76%
10 Year Est. Return
+308.24%
AUM
$548M
AUM Growth
+$7.66M
Cap. Flow
-$12M
Cap. Flow %
-2.19%
Top 10 Hldgs %
32.65%
Holding
154
New
7
Increased
23
Reduced
102
Closed
2

Top Sells

Rank Stock Value
1
EXC icon
Exelon
EXC
+$4.98M
2
STE icon
Steris
STE
+$4.1M
3
FCX icon
Freeport-McMoran
FCX
+$2.26M
4
ADI icon
Analog Devices
ADI
+$2.16M
5
JNJ icon
Johnson & Johnson
JNJ
+$1.91M

Sector Composition

Rank Sector Weight
1 Healthcare 24.56%
2 Industrials 19.03%
3 Technology 17.84%
4 Energy 9.49%
5 Utilities 7.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ADT
51
DELISTED
ADT Corp
ADT
$3.16M 0.58%
90,362
+9,200
+11% +$295K
YAO
52
DELISTED
Invesco China All-Cap ETF
YAO
$3.07M 0.56%
116,269
-5,000
-4% -$126K
DO
53
DELISTED
Diamond Offshore Drilling
DO
$2.88M 0.53%
58,000
+4,400
+8% +$219K
DLB icon
54
Dolby
DLB
$4.97B
$2.83M 0.52%
65,570
-5,850
-8% -$244K
TYC
55
DELISTED
TYCO INTL PLC COM SHS (IRL)
TYC
$2.81M 0.51%
58,946
+1,826
+3% +$82.3K
OGE icon
56
OGE Energy
OGE
$10.2B
$2.78M 0.51%
71,200
-300
-0.4% -$11K
HOLX
57
DELISTED
Hologic
HOLX
$2.77M 0.51%
109,150
+41,450
+61% +$969K
EXC icon
58
Exelon
EXC
$48.7B
$2.65M 0.48%
101,750
-195,264
-66% -$4.98M
MON
59
DELISTED
Monsanto Co
MON
$2.56M 0.47%
20,535
-850
-4% -$99.5K
XYL icon
60
Xylem
XYL
$29.7B
$2.54M 0.46%
64,970
-1,680
-3% -$62.8K
XBI icon
61
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$2.45M 0.45%
+47,646
New +$2.15M
SR icon
62
Spire
SR
$4.94B
$2.44M 0.45%
50,300
-1,500
-3% -$70.1K
CHL
63
DELISTED
China Mobile Limited
CHL
$2.37M 0.43%
48,650
-11,250
-19% -$540K
EWZ icon
64
iShares MSCI Brazil ETF
EWZ
$9.15B
$2.35M 0.43%
49,235
-700
-1% -$33.5K
LFCR icon
65
Lifecore Biomedical
LFCR
$167M
$2.35M 0.43%
188,350
-6,800
-3% -$80K
EPU icon
66
iShares MSCI Peru and Global Exposure ETF
EPU
$534M
$2.27M 0.42%
63,960
+400
+0.6% +$13.7K
AGX icon
67
Argan
AGX
$7.25B
$2.25M 0.41%
60,217
-6,700
-10% -$201K
EWA icon
68
iShares MSCI Australia ETF
EWA
$1.39B
$2.23M 0.41%
85,300
-600
-0.7% -$15.8K
WTS icon
69
Watts Water Technologies
WTS
$11.5B
$2.17M 0.4%
35,100
-1,364
-4% -$78.4K
JPM icon
70
JPMorgan Chase
JPM
$947B
$2.13M 0.39%
36,949
-1,577
-4% -$88.7K
EWC icon
71
iShares MSCI Canada ETF
EWC
$6.17B
$2.12M 0.39%
65,760
-1,100
-2% -$33.7K
MENT
72
DELISTED
Mentor Graphics Corp
MENT
$2.1M 0.38%
97,600
-600
-0.6% -$12.6K
LXFR icon
73
Luxfer Holdings
LXFR
$457M
$2.07M 0.38%
109,300
+3,700
+4% +$71K
ABT icon
74
Abbott
ABT
$187B
$2.06M 0.38%
50,497
-250
-0.5% -$9.82K
NEOG icon
75
Neogen
NEOG
$2.04B
$2.04M 0.37%
134,595
+8,400
+7% +$125K

Similar funds

John G. Ullman & Associates's Q2 2014 Portfolio in Review

As of Q2 2014, John G. Ullman & Associates held 154 positions worth $548M, up 1.4% from $540M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

John G. Ullman & Associates's Q2 2014 filing shows 7 new, 23 increased, 102 reduced and 2 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 47,646 shares worth $2.45M. The largest sale was Exelon, an estimated $4.98M.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 25% a quarter earlier, followed by Industrials and Technology.

  • John G. Ullman & Associates's largest Q2 2014 buy was State Street SPDR S&P Biotech ETF: 47,646 shares worth $2.45M.
  • John G. Ullman & Associates added most to Otter Tail in Q2 2014, an estimated $3.75M increase.
  • John G. Ullman & Associates's biggest Q2 2014 reduction was Exelon, cutting an estimated $4.98M.
  • John G. Ullman & Associates fully exited Halliburton in Q2 2014, selling an estimated $707K.
  • John G. Ullman & Associates's ten largest holdings make up 33% of its $548M portfolio in Q2 2014.
  • John G. Ullman & Associates opened 7 new positions and closed 2 in Q2 2014.
  • John G. Ullman & Associates's portfolio value rose 1.4% quarter-over-quarter to $548M.

Based on John G. Ullman & Associates's 13F filing for Q2 2014, filed 18 Jul 2014.